U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07420543) titled 'Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach' on Dec. 02, 2025.
Brief Summary: Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up,...